Evaxion Biotech A/S announced on April 28, 2025, new immune data for its lead personalized cancer vaccine candidate, EVX-01, presented at the American Association for Cancer Research (AACR) Annual Meeting. The data demonstrated that 80% of EVX-01 vaccine targets triggered a tumor-specific immune response.
This updated hit rate of 80% represents an increase from earlier interim analyses, which showed 71% at ASCO and 79% at ESMO 2024. The analysis included more long-term patient samples, reinforcing the potential of EVX-01 as an effective treatment for a broad range of solid tumors.
The company highlighted that the immune response observed was strong, long-lasting, and increased with additional booster immunizations. This further strengthens the clinical data package for EVX-01, which remains on track for its two-year clinical data readout in the second half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.